Synopsis
Recognise the rapid tempo of small-cell lung cancer, secure efficient tissue and staging, and coordinate platinum-based systemic therapy, radiotherapy and urgent complication management.
- Small-cell lung cancer is a high-grade neuroendocrine malignancy with early dissemination, rapid doubling and initial treatment sensitivity followed by a substantial risk of relapse.
- Obtain pathological confirmation promptly, but design one efficient diagnostic and staging sequence because serial low-yield procedures can consume a clinically important treatment window.
- Use TNM staging and also describe limited-stage disease when it can be encompassed within a tolerable radical radiotherapy field; extensive-stage disease exceeds that practical boundary.
- Baseline staging generally includes contrast CT, brain imaging and, when radical treatment is contemplated, PET-CT or other tests that resolve curative-field uncertainty.
- Fit limited-stage disease is usually treated with platinum-etoposide and early concurrent thoracic radiotherapy; timing and agent choice require specialist assessment of toxicity and treatment volume.
- Eligible untreated extensive-stage disease may receive atezolizumab with carboplatin and etoposide under NICE TA638, followed by maintenance atezolizumab according to the licensed pathway.
- Hyponatraemia, ectopic ACTH effects, Lambert-Eaton syndrome, superior vena cava obstruction, brain metastases and spinal cord compression can be the presenting clinical problem.
- At relapse, the previous response duration, performance status, organ function, disease distribution and current NICE options determine whether to rechallenge, change systemic treatment, use radiotherapy or focus on symptoms.
Key red flags
Seizure, new focal neurology, altered consciousness or raised-intracranial-pressure features requires urgent brain imaging and acute management before routine outpatient staging.
Airway compromise or neurological symptoms with superior vena cava obstruction needs emergency multidisciplinary care; do not delay stabilisation for an ideal tissue sequence.
Back pain with weakness, sensory level or bladder disturbance suggests metastatic cord compression and must enter the emergency pathway immediately.
Severe symptomatic hyponatraemia can cause seizures or coma; manage the neurological emergency with expert biochemical monitoring while treating the cause.
Fever or haemodynamic deterioration after chemotherapy is neutropenic sepsis until assessed and needs immediate local protocol treatment.
Investigation priorities
Define primary, nodal, hepatic, adrenal and other accessible disease before sampling.
Management branches
Imaging or clinical tempo suggests central high-grade lung cancer compatible with SCLC.
- Identify immediate airway, neurological, metabolic and venous-obstruction emergencies, treating these in parallel with diagnostic planning and early acute-oncology contact.
- Use contrast CT to select one safe high-yield biopsy route, often bronchoscopic or EBUS for central disease, and alert pathology that rapid definitive classification is needed.
- Complete brain imaging and decision-changing extracranial staging without duplicating tests, using PET-CT when a radical limited-stage field remains plausible.
- Bring pathology, TNM, practical limited or extensive category, performance and patient preference to thoracic MDT promptly and agree a documented treatment start plan.